Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat

@article{Hotta2008StratifiedAF,
  title={Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat},
  author={Nigishi Hotta and Ryuzo Kawamori and Yoshihito Atsumi and Motoi Baba and Hideki Kishikawa and Jiro Nakamura and Shigeo Oikawa and Nobuhiro Yamada and Hitoshi Yasuda and Yukio Shigeta},
  journal={Diabetic Medicine},
  year={2008},
  volume={25},
  pages={818 - 825}
}
AIMS The long-term efficacy of epalrestat, an aldose reductase inhibitor, in improving subjective symptoms and nerve function was comprehensively assessed to identify patients with diabetic peripheral neuropathy who responded to epalrestat treatment. METHODS Stratified analyses were conducted on data from patients in the Aldose Reductase Inhibitor-Diabetes Complications Trial (ADCT). The ADCT included patients with diabetic peripheral neuropathy, median motor nerve conduction velocity > or… CONTINUE READING
9 Citations
27 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Polyolpathway: aldose reduct

  • EL Feldman, KA Sullivan, MJ. Stevens
  • Int Rev Neurobiol
  • 2002

Similar Papers

Loading similar papers…